Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Santa Monica, CA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Solvang, CA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Solvang, CA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Valencia, CA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Valencia, CA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Aurora, CO
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Gainesville, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
New Port Richey, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Macon, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Marietta, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Alton, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Alton, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Skokie, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Elkhart, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Elkhart, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Mishawaka, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
South Bend, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Westville, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Westville, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lexington, KY
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lansing, MI
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Minneapolis, MN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Southaven, MS
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Southaven, MS
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Grand Island, NE
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Grand Island, NE
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Kearney, NE
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Kearney, NE
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Henderson, NV
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Henderson, NV
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
New York, NY
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Charlotte, NC
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Bismarck, ND
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Oklahoma City, OK
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Portland, OR
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
West Reading, PA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
West Reading, PA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Bartlett, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Bartlett, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Germantown, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Memphis, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Niles, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Niles, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Oxford, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Oxford, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lubbock, TX
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lubbock, TX
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Temple, TX
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Temple, TX
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Salt Lake City, UT
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Fitzroy,
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Fitzroy,
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Saint Joseph, MI
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Saint Louis, MO
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Cancer Center
mi
from
Bronx, NY
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
AZ Klina Brasschaat
mi
from
Brasschaat,
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
AZ Klina Brasschaat
mi
from
Brasschaat,
Click here to add this to my saved trials